{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019795","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.320923+00:00","generated_at":"2026-06-07T12:31:41.610148+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities","bullets":["First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.","BP1002 uses RNAi to limit Bcl-2 protein production, offering potential treatment for venetoclax-resistant patients.","Treatment cycle: two doses per week for 4 weeks (8 doses over 28 days).","Phase 1b portion will assess BP1002 in combination with decitabine after monotherapy cohorts.","National PI is Dr. Gail Roboz, director of Clinical and Translational Leukemia Program at Weill Cornell."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019795","json":"https://secwatch.observer/filing/0001558370-23-019795.json","markdown":"https://secwatch.observer/filing/0001558370-23-019795.md","text":"https://secwatch.observer/filing/0001558370-23-019795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/0001558370-23-019795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/bpth-20231214x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:31:41.610148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}